Results 131 to 140 of about 98,172 (269)

The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion [PDF]

, 1996
Anderson Sm, J Mladenovic
openalex   +1 more source

BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

, 1991
Alexander J. Muller, Judy Young, Ann Marie Pendergast, Mark Pondel, NR Landau, Dan R. Littman, Owen N. Witte   +6 more
openalex   +1 more source

Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR) [PDF]

, 1996
Stefan Nagel
openalex   +1 more source

Fluorescence in‐situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon‐α therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation [PDF]

, 1997
J. Thiele, Beate Schmitz, H Gross, Hans Michael Kvasnicka, N. Niederle, L.-D. Leder, R. Fischer   +6 more
openalex   +1 more source

Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia

Biomedical Technology
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong, Dingrui Nie, Xueting Peng, Kangjie Qiu, Jinyi Liu, Zhangshuai Dai, Xianfeng Zha, Songnan Sui, Weini Li, Weizhang Wang, Cunte Chen, Yangqiu Li, Chengwu Zeng   +12 more
doaj  

BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia [PDF]

, 1996
Véronique Maguer‐Satta, AL Petzer, AC Eaves, CJ Eaves   +3 more
openalex   +1 more source

Belt and braces for BCR–ABL [PDF]

Nature Reviews Drug Discovery, 2017
openaire   +3 more sources

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]

Pharmaceuticals (Basel)
Hajjo R, Sabbah DA, Alhaded R, Alquabe'h A, Bardaweel SK.   +4 more
europepmc   +1 more source

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. [PDF]

J Enzyme Inhib Med Chem, 2023
El-Damasy AK, Jin H, Park JW, Kim HJ, Khojah H, Seo SH, Lee JH, Bang EK, Keum G.   +8 more
europepmc   +1 more source

Specificity of bcr-abl antisense oligonucleotides.

, 1995
Item does not contain ...
Smetsers, A.F.C.M., Mensink, E.J.B.M.
openaire   +2 more sources